SCHEMBL14026

SCHEMBL14026

O=C(NC1CCNCC1)c1c(F)cc(-c2cc3cn(-c4ccc(CNCCCF)cc4)c(=O)nc3[nH]2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 3/20 0.35
CDK2 P24941 3/20 0.35
AKT1 P31749 2/20 0.35
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNA1 P78396 1/20 0.33
PARP1 P09874 2/20 0.33
KDM1A O60341 1/20 0.32
WNT1 P04628 1/20 0.32
DYRK1A Q13627 1/20 0.32
DHODH Q02127 1/20 0.32
KHK P50053 2/20 0.31
TNK2 Q07912 1/20 0.31
TNK1 Q13470 1/20 0.31
ACKR3 P25106 1/20 0.31
NTRK1 P04629 2/20 0.30
RIPK1 Q13546 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14306 0.89 CDK2 (0.38) CCNA2CDK2AKT1CDK1CCNB1
SCHEMBL14512 0.85 RIPK1 (0.41) DHODHKHKNTRK1RIPK1
SCHEMBL14303 0.85 HDAC4 (0.37) CCNA2CDK2AKT1PARP1KDM1A
SCHEMBL13856 0.80 KLKB1 (0.38) KHKACKR3NTRK1
SCHEMBL14311 0.79 BRD4 (0.33)
SCHEMBL14232 0.79 RIPK1 (0.39) KDM1ADHODHKHKRIPK1
SCHEMBL14825 0.78 SMYD3 (0.36) KHKACKR3NTRK1
SCHEMBL14503 0.78 MC4R (0.35) PARP1
SCHEMBL13804 0.77 RIPK1 (0.37) KDM1ADHODHKHKRIPK1
SCHEMBL14513 0.77 RIPK1 (0.46) DHODHKHKRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT CCNA2 4473/4885CDK2 4787/4885AKT1 3953/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT CCNA2 4473/4885CDK2 4787/4885AKT1 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.